US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

Interestingly, celebrities like Elon Musk, Oprah Winfrey and Amy Schumer, among others, have also endorsed drugs like Ozempic ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

Kyverna Therapeutics said it named Naji Gehchan as its chief medical and development officer. The clinical-stage biopharmaceutical company on Tuesday said that Gehchan comes from Eli Lilly, where he ...

Lilly will also conduct a conference call that ... young biotechs developing game-changing technologies to big pharma or medical device players selling blockbuster drugs and paying out dividends ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

In the latest trading session, Eli Lilly (LLY) closed at $753.98, marking a +1.57% move from the previous day. This move outpaced the S&P 500's daily gain of 0.61%. Meanwhile, the Dow gained 0.3%, and ...

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...

Medical devices stocks are in a strong position “and must be bought,” according to Rich Ross, head of Technical Analysis at Evercore ISI, in a note. The iShares U.S. Medical Device ETF (NYSEARCA:IHI) ...

Lilly already has LGLs in four locations in ... patients in this country can reap the rewards of the revolution in medical science unfolding before our eyes," commented Health and Social Care ...